Medicine details

ImageEnso 30
NameEnso 30
DosageCapsule
Generic NameLansoprazole
Classes Gastrointestinal Agent
Antiulcerants
Proton Pump Inhibitor (PPI)
Diseases Dyspepsia
Gastrointestinal Disease
GERD (Gastroesophageal Reflux Disease)
Heart Burn
Ulcer
CompanyKemiko Pharmaceuticals Ltd.

Drug Package Details

Strength30 mg
Storage Condition
Origin CountryBangladesh
Commercial Pack20
Price per pack120.00
Cost per pack105.60
Package unit5 caps strip
Price per unit6.00
Cost per unit5.28
Discount0
Coupon
Remarks

Lansoprazole

Lansoprazole is indicated for the following conditions

  • Short-Term Treatment of Active Duodenal Ulcer
  • H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence
  • Maintenance of Healed Duodenal Ulcers
  • Short-Term Treatment of Active Benign Gastric Ulcer
  • Healing of NSAID-Associated Gastric Ulcer
  • Risk Reduction of NSAID-Associated Gastric Ulcer
  • Gastroesophageal Reflux Disease (GERD)
  • Maintenance of Healing of Erosive Esophagitis
  • Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
  • Treatment of duodenal ulcer: The recommended dose is 30 mg once daily for 2 weeks. In patients not fully healed within this time, the medication is continued at the same dose for another two weeks.
  • Treatment of gastric ulcer: The recommended dose is 30 mg once daily for 4 weeks. The ulcer usually heals within 4 weeks, but in patients not fully healed within this time, the medication may be continued at the same dose for another 4 weeks.
  • Reflux esophagitis: The recommended dose is 30 mg once daily for 4 weeks. In patients not fully healed within this time, the treatment may be continued at the same dose for another 4 weeks.
  • Prophylaxis of reflux esophagitis: 15 mg once daily. The dose may be increased up to 30 mg daily as necessary.
  • Eradication of Helicobacter pylori: The recommended dose is 30 mg of lansoprazole twice daily for 7 days in combination with one of the following:
    • clarithromycin 250-500 mg twice daily + amoxicillin 1 g twice daily
    • clarithromycin 250 mg twice daily + metronidazole 400-500 mg twice daily
  • NSAID-Associated Gastric Ulcer: 30 mg once daily for four weeks. In patients not fully healed the treatment may be continued for another four weeks. For patients at risk or with ulcers that are difficult to heal, a longer course of treatment and/or a higher dose should probably be used.
  • Risk Reduction of NSAID-Associated Gastric Ulcer: 15 mg once daily. If the treatment fails the dose 30 mg once daily should be used.
  • Symptomatic gastro-oesophageal reflux disease: The recommended dose is 15 mg or 30 mg daily. Relief of symptoms is obtained rapidly. Individual adjustment of dosage should be considered. If the symptoms are not relieved within 4 weeks with a daily dose of 30 mg, further examinations are recommended.
  • Zollinger-Ellison syndrome: The recommended initial dose is 60 mg once daily. The dose should be individually adjusted and the treatment should be continued for as long as necessary. Daily doses of up to 180 mg have been used. If the required daily dose exceeds 120 mg, it should be given in two divided doses.
  • Hepatic impairment: Patients with moderate or severe liver disease should be kept under regular supervision and a 50% reduction of the daily dose is recommended

Commonly reported side effects include-

  • Headache
  • Nausea
  • Abdominal pain
  • Diarrhea
  • Vomiting
  • Flatulence
  • Upper respiratory tract infection (pharyngitis, sinusitis)
  • Dizziness
  • Asthenia
  • Cough
  • Symptomatic response to therapy with Lansoprazole does not preclude the presence of gastric malignancy.
  • Published observational studies suggest that PPI therapy like Lansoprazole may be associated with an increased risk of Clostridium difficile associated diarrhea, especially in hospitalized patients.
  • Lansoprazole therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer).
  • Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months
  • Concomitant use of PPIs with methotrexate may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities.

Contraindication

Lansoprazole is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. Examples of benzimidazole derived drugs include-

There is no know food or drink which can affect this medication. But if you are taking any vitamins, food supplements, or herbal products, please talk to your pharmacist/doctor.

There is no known contraindications of Lansoprazole sodium in terms of health and conditions.